WALTHAM, Mass. & FT LAUDERDALE, Fla.--(BUSINESS WIRE)--Nipro Diagnostics, Inc. and NeuroMetrix, Inc. (Nasdaq: NURO) today announced their collaboration to evaluate opportunities for NC-stat® | DPNCheck™ in retail medical clinics. NC-stat DPNCheck is a rapid, quantitative, point-of-care test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy (DPN). DPN affects more than half of people with diabetes and may lead to foot ulcers and limb amputation, as well as pain and an overall reduction in quality of life. Nipro and NeuroMetrix believe that this test may address the unmet medical need for better and cost-effective approaches to detecting and monitoring DPN.
